News >

Novel Agents, Approaches Drive Progress in HER2+ Breast Cancer

Caroline Seymour
Published: Friday, Mar 01, 2019

Erika P. Hamilton, MD

Erika P. Hamilton, MD
Several data sets from studies presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) had an immediate impact on patients with HER2- positive breast cancer, explained Erika P. Hamilton, MD. For patients with low HER2 expression, with brain metastases, and those with hormone- and HER2-driven disease, therapies such as antibody– drug conjugates (ADCs), HER2-directed agents, and CDK4/6 inhibitors are showing potential.

State of the Science Summit™ on Breast Cancer, Hamilton, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, shared insight on the management of patients with HER2-positive breast cancer and strategies aimed at targeting treatment resistance and toxicity.

OncLive: What are some of the latest treatment approaches in HER2-positive breast cancer?

Hamilton: Several new [agents] have come into the HER2 arena over the past few months. At the 2018 SABCS, we saw data from PHARE, which contrasted with what we saw from PERSEPHONE. Both of these studies looked at a shorter duration of trastuzumab—specifically, 6 months of therapy versus the traditional 12 months. Although the hazard ratios were quite similar, [there were] different conclusions based on the statistical design of the 2 trials. PHARE concluded that 6 months of therapy was inferior to 12, whereas PERSEPHONE concluded noninferiority between the 2 treatment durations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication